Proteomics and gynecological cancer

Makedou K, Prapas N, Kourtis A, Makedos G

4th Department of Obstetrics and Gynecology, University of Thessaloniki, Thessaloniki, Greece

Correspondence: Makedou K, 45 Aristotelous St, GR-55 236, Thessaloniki, Greece.

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 


 

Abstract

Proteomics is the study of the complete protein complement of the human genome, the “proteome”. Various technologies have been developed for the purposes of proteomics, such as mass spectrometry. In oncology, proteomics can provide the identification of a panel of proteins, which can be used as biomarkers for early cancer detection, for disease stage determination, for the application of the appropriate target therapy, and for better disease monitoring, and these can be achieved with a greater sensitivity than with technologies used in the past. Proteomics can have important applications in ovarian, breast and endometrial cancer, offering a new perspective in clinical practice.
 

Key words: proteomics; cancer; biomarkers; ovarian; breast